• Molecular NameCeforanide
  • SynonymCeforanido [INN-Spanish]; Ceforanidum [INN-Latin]
  • Weight519.563
  • Drugbank_IDDB00923
  • ACS_NO60925-61-3
  • Show 3D model
  • LogP (experiment)-1.044
  • LogP (predicted, AB/LogP v2.0)-1.55
  • pkaN/A
  • LogD (pH=7, predicted)-5.05
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-1.14
  • LogSw (predicted, AB/LogsW2.0)19.72
  • Sw (mg/ml) (predicted, ACD/Labs)0.48
  • No.of HBond Donors5
  • No.of HBond Acceptors13
  • No.of Rotatable Bonds10
  • TPSA244.23
  • StatusFDA approved, US withdrawn
  • Administrationintramuscular administration
  • PharmacologyA second-generation cephalosporin antibiotic.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein binding81.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmThe major drug elimination route was urinary excretion with 85% of the dose being excreted unchanged in the urine within 12 hr, and no metabolites with antibiotic activity were observed in urine.
  • Half life2.6~2.98 h
  • ExcretionRenal
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityAdverse effects following overdosage include nausea, vomiting, epigastric distress, diarrhea, and convulsions.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A